Who are Loceryl Nail Lacquer's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Loceryl NL + Cosmetic varnish, Loceryl NL 15 months, Amorolfine (Antifungal).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/loceryl-nail-lacquer.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Loceryl Nail Lacquer — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Loceryl Nail Lacquer (Loceryl Nail Lacquer) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Morpholine antifungal. Area: Dermatology.

marketed Morpholine antifungal Lanosterol 14α-demethylase (CYP51) Dermatology Small molecule Live · refreshed every 30 min

Target snapshot

Loceryl Nail Lacquer (Loceryl Nail Lacquer) — Galderma R&D. Amorolfine inhibits fungal sterol synthesis by blocking lanosterol demethylase, disrupting the integrity of the fungal cell membrane.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Loceryl Nail Lacquer TARGET	Loceryl Nail Lacquer	Galderma R&D	marketed	Morpholine antifungal	Lanosterol 14α-demethylase (CYP51)
Loceryl NL + Cosmetic varnish	Loceryl NL + Cosmetic varnish	Galderma R&D	marketed	Morpholine antifungal	Δ14-steroid reductase and Δ8→Δ7-isomerase (ergosterol biosynthesis pathway)
Loceryl NL 15 months	Loceryl NL 15 months	Galderma R&D	marketed	Morpholine antifungal	Fungal sterol synthesis enzymes (Δ14-reductase, Δ8-Δ7-isomerase)
Amorolfine (Antifungal)	Amorolfine (Antifungal)	Pierre Fabre Dermo Cosmetique	marketed	Morpholine antifungal	Lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Morpholine antifungal class)

Galderma R&D · 3 drugs in this class
Pierre Fabre Dermo Cosmetique · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Loceryl Nail Lacquer — Competitive Intelligence Brief. https://druglandscape.com/ci/loceryl-nail-lacquer. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing